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INTRODUCTION 
 
Pemphigus is the commonest autoimmune vesiculobullous disorder on 
the Indian subcontinent.1  A study on mortality among inpatients in 
dermatology from India found pemphigus vulgaris to be the commonest 
disorder to cause death.2  Pemphigus is an autoimmune disease that results in 
blistering of the skin and oral cavity, which if left untreated is almost always 
fatal. It is caused by autoantibodies directed against cell-surface antigens on 
keratinocytes, which when targeted lose their cellular adhesion properties and 
separate from one another to form blisters within the epidermis.3  It is 
classified into two major subtypes: pemphigus vulgaris (PV) and pemphigus 
foliaceus (PF).4 Differences in the particular antigens targeted by the 
antibodies and in the distribution of these antigens in the different regions of 
the body and in the separate layers of the epidermis result in different clinical 
manifestations of the disease.3 The diagnosis of pemphigus rests upon the 
demonstration of these autoantibodies by immunofluorescence techniques 
whilst the differentiation of PV and PF relies upon the combination of clinical 
and histological features. Although Western immunoblotting and 
immunoprecipitation can be used to identify the target antigen in cases of 
pemphigus, these are both time consuming qualitative techniques which are 
impractical for routine screening of large number of serum samples.5 
Pemphigus autoantibodies are mainly directed against the desmosomal 
adhesion molecules, desmoglein 1 (Dsg 1) and desmoglein 3 (Dsg 3). The 
production of recombinant Dsg 1 and Dsg 3 antigens has made possible the 
development of enzyme linked immunosorbent assays (ELISAs).6 Recently  
Dsg 1 and Dsg 3 ELISAs  have been shown to provide a simple, sensitive and  
highly specific assay for the diagnosis of patients with PV and PF.7  Since 
precise diagnosis of these two diseases is important for determining treatment 
plans and prognosis, sensitive and specific testing for the pathogenic 
autoantibodies found in PV and PF would be helpful in the clinical 
management and laboratory investigation of these two severe autoimmune 
diseases.6 
As there is a paucity of studies from India,8,9 the present study is an 
attempt to validate ELISA estimation of desmoglein antibodies as a diagnostic 
test for pemphigus and to study the prevalence of  desmoglein antibodies in 
the various clinical types of pemphigus in Indian patients. 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
AIMS OF THE STUDY 
 
1) To validate ELISA estimation of Dsg 1 and Dsg 3 antibodies in 
pemphigus as a diagnostic test in Indian patients. 
 
2)  To study the correlation of Dsg 1 and Dsg 3 antibody titres with  
a)  mucosal  and cutaneous involvement  
           b)  severity of disease.   
 
3)  To investigate the prevalence of Dsg 1 and Dsg 3 antibodies in the 
different pemphigus variants. 
 
 
 
 
REVIEW OF LITERATURE 
Introduction: 
Pemphigus is an autoimmune blistering disease targeting skin and 
mucous membranes. It is divided into two major subtypes: PV and PF. 
Autoantibodies in pemphigus play a primary pathogenic role in initiating blister 
formation. Currently, the diagnosis of pemphigus largely relies on 
immunoflourescence testing utilising direct immunoflourescence (DIF) staining 
and indirect immunoflourescence (IIF). Despite the different antigens involved 
in each disease the cell staining pattern using DIF or IIF is virtually identical 
making it difficult to distinguish between PV and PF. Immunoblotting and 
immunoprecipitation studies have demonstrated the target molecules of 
pemphigus to be a 130-kDa glycoprotein in PV and a 160-kDa glycoprotein in 
PF.6 
 
History: 
Pemphigus is derived from the Greek term, pemphix, meaning blister or 
bubble.10  De Sauvages in 1760 coined the word ‘pemphigus’.11 In 1943 
Civatte reported histopathological findings in various types of pemphigus and 
coined the term acantholysis. In 1964 Beutner and Jordan demonstrated that 
autoantibodies are directed against the squamous epithelial cell surface in 
pemphigus. In 1982 Anhalt et al constructed an animal model for pemphigus 
by passive transfer of immunoglobulins (IgG)  from patients to neonatal 
mice.12 
Definition: 
The term ‘pemphigus’ refers to a group of autoimmune blistering 
diseases of skin and mucous membranes that are characterized histologically 
by intraepidermal blisters due to acantholysis and immuopathologically by in 
vivo bound and circulating IgG directed against the cell surface of 
keratinocytes.13 
 
Demographics and Incidence: 
The mean age of onset of pemphigus in India has been reported to be 
36.9 years and 39.5 years in different studies, whereas a higher  mean age of 
onset of 52.7 years has been reported  from United Kingdom (UK).14,15 In India 
no sex predilection was observed.15 In the UK the commonest subtypes are 
PV and PF  with equal prevalence (44.4%), but in India PV is the most 
frequent (79.4%), while PF is uncommon (7.6%) and with equal prevalence of 
the other subtypes.14 The exact incidence of disease and prevalence of PV 
compared with that of PF depend very much on the population studied. The 
highest incidence of pemphigus is among Jews of Ashkenazi origin.16 
 
Etiology:  
The predisposition to pemphigus is linked to genetic factors. Certain 
major histocompatibility complex (MHC) class II genotypes, in particular alleles 
of HLA-DRB1*04 and DRB1*14 subtypes are common in patients with PV 
across racial barriers.10   In India a haplotype related to DSG3*TCCTC is 
significantly associated with  PV  as it is found in 20% of patients vs 6% 
controls (p=0.002).17 Pemphigus may also occur in patients with other 
disorders characterised by immunological disturbances.18   Viral  DNA has 
been detected in some skin biopsies or peripheral blood mononuclear cells 
from pemphigus patients.19,20   Endemic pemphigus foliaceous, also known as 
fogo selvagem, common in rural parts of South America is probably triggered 
by an environmental factor.21 Drugs may exacerbate or induce pemphigus.10 A 
distinctive form of pemphigus has been described in association with a variety 
of underlying neoplasms.22 
 
Types: 10  
The different types of pemphigus is shown in Table 1. 
 
Pathophysiology of  pemphigus: 
PV and PF are characterized by intraepidermal blister formation due to 
loss of cell adhesion of keratinocytes and immunopathologically by the 
findings of in vivo bound and circulating IgG directed against the cell surface of 
keratinocytes.6   
Pathogenicity of autoantibodies in pemphigus: 
Autoantibodies in pemphigus play a primary pathogenic role in initiating 
blister formation12  Disease activity in patients often correlates with anti-cell 
surface antibody titre as determined by IIF.23  Also neonates of mothers with 
PV may have transient disease due to maternal IgG that crosses the placenta. 
As maternal antibody is catabolised, the disease subsides.24 In skin organ 
culture IgG alone without complement or inflammatory cells from patients with 
pemphigus can induce loss of  cell-cell adhesion, with the same histology as 
seen in patients. Passive transfer of IgG from patients sera to normal mice 
results in loss of cell-cell adhesion and blisters with typical histological 
findings.12,25 However between 40 and 71% of immediate relatives of 
pemphigus patients have been found to be carriers of low titre PV 
autoantibodies.26  Anti-intercellular substance (ICS) antibodies can be 
produced in several clinical conditions in which there is damage to the 
epidermis.27  Antibodies that mimic or that may give in vitro deposition in 
stratified squamous epithelium in the absence of pemphigus have been 
reported in bullous pemphigoid, cicatricial pemphigoid, burns, toxic epidermal 
necrolysis, penicillin allergy and systemic lupus erythematosus.28  The release 
of epidermal antigens caused by physical injury or  biochemical insults may 
permit exposure of these antigens to the immune system with resultant 
production of anti-ICS antibodies. However in such cases these antibodies are 
only transiently present.27   
 
Proposed mechanisms of acantholysis: 
The mechanisms whereby these pemphigus antibodies induce 
acantholysis is an area of active investigation.29 
Organ and cell culture studies have suggested that binding of 
pemphigus autoantibodies to the keratinocyte cell surface causes release of a 
protease which in turn causes acantholysis.30,31,32 The identity of this 
proteolytic enzyme is in dispute. Some studies suggest that it is plasminogen 
activator that, once released by keratinocytes activates, plasminogen to 
plasmin which in turn causes  acantholysis.33 
The role of complement in  blister formation is controversial. Pemphigus 
sera are capable of causing acantholysis in skin organ culture and detachment 
of keratinocytes in cell culture without complement.26,30   However complement 
does enhance pemphigus antibody mediated detachment of cultured 
epidermal cells, probably by damage to cell membranes.34,35  
Recent studies have also proposed a novel explanation for acantholysis in 
pemphigus, based on the basal cell shrinkage hypothesis.36  
There is abundant evidence from various studies that desmogleins and 
anti-desmoglein antibodies are directly involved in causing blisters in PV and 
PF. Patients with PF have anti-Dsg1 antibodies6,37  and patients with PV have 
anti-Dsg 3 antibodies with greater than 50% having, in addition, anti-Dsg1 
antibodies.6,38  Patients with PV limited to mucous membranes usually have 
only anti-Dsg3 antibodies6,39,40  whereas, PV patients who develop extensive 
skin involvement in addition to oral involvement develop anti-Dsg1 antibodies 
in addition to anti-Dsg3 antibodies.6,39,41  Passive transfer studies in neonatal 
mice confirm the findings in humans that both anti-Dsg 3 and anti-Dsg 1 
antibodies are necessary for efficient blister formation in skin. In neonatal 
mouse model of pemphigus, PV sera with anti-Dsg 3 alone are much less 
efficient at causing skin blisters than those with anti-Dsg 3 and anti-Dsg 1. 
Furthermore, addition of small amounts of anti-Dsg 1 antibodies from PF sera 
dramatically enhances the formation of PV skin blisters caused by PV sera 
containing only anti-Dsg 3 antibodies.42  Inactivation of Dsg 3 by genetic 
means causes lesions in mice that are strikingly similar to those seen in 
pemphigus patients with anti-Dsg 3 antibodies.43  Also pathogenic activity can 
be adsorbed from PF and PV sera by the extracellular domains of Dsg 1 and 
Dsg 3 respectively.44  Dsg 3null mice can be immunised with Dsg 3 to produce 
anti-Dsg 3 antibodies that cause typical lesions when transferred to Dsg 3+/+ 
mice.45 
However Nguyen et al46 propose that antibodies against keratinocyte 
antigens other than desmoglein 1 and 3 can induce pemphigus vulgaris like 
lesions. Dsg 3 lacking mice were injected with PV IgGs that did not cross react 
with the 160 kDa Dsg 1 or its 45 kDa immunoreactive fragment and that 
showed no reactivity with recombinant Dsg 1. These PV IgGs caused gross 
skin blisters with PV like suprabasal acantholysis and stained perilesional 
epidermis in a fish net like pattern indicating that  the PV phenotype can be 
induced without anti-Dsg3 antibody. The anti-Dsg1 antibody was also not 
required as its presence in PV IgG does not alter the PV like phenotype in skin 
organ cultures and because pemphigus foliaceous IgGs produce a distinct 
phenotype in Dsg 3null mice.  
Countering the theory proposed by Nguyen et al,  Stanley et al47 
contend that all passive transfer experiments that resulted in blisters were 
performed with Dsg 3null mice which already have altered adhesion and that 
there is no evidence that non Dsg antibodies produce pemphigus lesions in 
normal  mice or humans. Amagai et al48 have opined that although other 
antibodies may be involved, there is little to validate this alternative theory and 
that in fact it has been clearly shown that mouse and human anti-Dsg 
antibodies alone cause typical blisters of pemphigus.   
There have been recent discoveries of two new human keratinocyte 
molecules targeted by disease-causing PV IgGs namely (a) the α9 
acetylcholine receptor with dual muscarinic and nicotinic pharmacology and (b) 
pemphaxin a novel annexin that can act as a acetylcholine receptor. 49,50 
It has been proposed that acantholysis in pemphigus  is mediated by at 
least two complementary pathways, namely, (1) anticholinergic receptor 
antibody that weakens intercellular adhesions between keratinocytes via 
inactivation of the cholinergic receptor mediated  physiologic control of  
cadherin (Dsg) expression and/or function that causes dyshesion, cell 
detachment and rounding up or acantholysis and (2) antibodies to adhesion 
molecules that prevent formation of new desmosomes in acantholytic 
keratinocytes by blocking the extracellular domain of desmosomal cadherins 
that mediate homophilic adhesion. These separate pathophysiological  
pathways targeting 2 different types of keratinocyte cell surface molecules (i.e 
cholinergic receptor and desmoglein) may explain high affinity and low affinity 
binding of pemphigus IgGs to keratinocytes.51 
Stanley et al48 further opine that though some interesting and significant 
observations about cholinergic recepors in keratinocytes and their adhesion 
have been made there is no convincing evidence for their role in the 
pathogenesis of pemphigus and that the significance of non desmoglein 
antibodies to the pathophysiology of pemphigus remains to be proved.48 
 
Distribution, structure and function of desmosomes: (Fig. 1) 
Desmoglein, a cadherin type of adhesion molecule is found in 
desmosomes. Desmosomes are cell–cell complexes found primarily in 
epithelial tissues but also in the meninges, the dendritic reticulum cells of 
lymph node follicles and the myocardium. They represent the major 
intercellular adhesion mechanism in both follicular and interfollicular epidermis,  
anchoring  keratin  intermediate filaments  to the cell membrane and bridging 
adjacent keratinocytes and allowing them to withstand trauma. Initially 
described as discontinuous button like structures of epithelia, desmosomes 
are now also recognized as signaling intermediates composed of an emerging 
and expanding network of tissue specific membrane and membrane-
cytoskeletal linker molecules.52 The basic function of the desmosome is to 
attach the keratin cytoskeleton of one cell to the cytoskeleton of adjacent cell. 
There must be intermediate proteins to do this, because keratins do not cross 
the cell membrane. In the desmosome the multiple proteins that compose the 
structure can be clumped into 3 functional groups (1) the keratin filaments that 
link to (2) the “plakin” proteins which are found just under the plasma 
membrane and link to (3) the transmembrane proteins, desmoglein. These 
desmogleins then hook into desmoglein/plakin/keratins in the adjacent cell and 
complete the anchorage of both cells’ cytoskeletons to each other (keratin-
plakin-desmoglein-plakin-keratin).53 
 
Desmogleins and their expression : 
Desmosomal cadherins are of two types,  desmogleins and desmocollin,  
both of which occur as 3 isoforms, Dsg1, Dsg 2, and Dsg 3 and Dsc 1, Dsc 2, 
and Dsc 3.54       
Desmoglein 3, a 130–kd transmembrane glycoprotein and desmoglein1, 
a 160-kd glycoprotein of the cadherin family, mediate weak calcium dependent 
homophilic cell- cell adhesion of epidermal keratinocytes. In the skin, Dsg 3 is 
expressed in the lower part of the epidermis mainly in the basal and immediate 
suprabasal layers, while Dsg 1 is expressed throughout the epidermis, but 
more intensely in the superficial layers. In mucous membranes Dsg 3 is highly 
expressed throughout the mucosa while expression of Dsg 1 is much less than 
in the skin.55  Desmoglein 2 is expressed in all desmosome possessing tissues 
including simple epithelia and myocardium whereas Dsg 1 and Dsg 3 are 
usually restricted to stratified squamous epithelia where blister formation is 
found in pemphigus.56,57  Since either desmoglein can mediate adhesion, the 
reason for their differential distribution is not known.58 
Desmogleins are targeted in skin-blistering diseases such as 
pemphigus, staphylococcal scalded skin syndrome  and bullous impetigo.59,60 
 
Desmogleins in the various clinical forms of pemphigus: (Table 2) 
The distinct forms of pemphigus are determined by which specific 
desmoglein is targeted and whether additional protein antigens are also 
involved. Although there are three immunologic variants there are many 
clinical variants. In paraneoplastic pemphigus a much broader range of 
desmosomal proteins are targeted because the plakin proteins are involved.  
In pemphigus foliaceus blistering occurs in and around the granular cell 
layer of the epidermis  These patients have antibodies against desmoglein 1. 
This desmoglein is expressed mainly in the upper layers of the epidermis and 
antibodies binding  to it cause acantholysis only where it is primarily expressed. 
Desmoglein  1 is present in the oral mucosa but mucosal lesions never occur 
because there is co expression of Dsg 3 in the oral epithelium and this is able 
to keep the cells from detaching. Pemphigus vulgaris is usually characterized 
by oral lesions and progression to cutaneous lesions. In PV, antibodies impair 
the adhesive function of Dsg 3 and cause acantholysis in the oral cavity. As 
PV progresses many but not all patients will experience cutaneous disease. 
This seems to be caused by spread of the antibody response and 
development of antibodies against both Dsg 1 and 3.53 
 
Intramolecular epitope spreading in pemphigus vulgaris: 
At the early stage of the disease (mucosal PV) patients display only 
autoimmunity to Dsg 3  and develop mucosal blisters, while at the later stages 
of the disease (mucocutaneous PV) patients exhibit non-cross reactive 
autoimmunity to both Dsg 3 and Dsg 1 and acquire cutaneous as well as 
mucosal blisters. At these two disease stages, Dsg3 autoantibodies exhibit 
different tissue binding patterns and pathogenic activities, suggesting that they 
may  recognize  distinct  epitopes.61  Salato et al61 tested this hypothesis and 
demonstrated that autoantibodies from the majority of  mucosal PV patients 
target epitopes at the COOH-terminal portion of  the Dsg 3 ectodomain. 
Interestingly only antibodies against the Dsg 3 NH2-terminal epitope are able 
to bind to human skin. They also discovered that the intramolecular epitope 
spreading from Dsg 3 (87-566) to Dsg 3 (1-88) is a critical step that precedes 
the intermolecular epitope spreading from Dsg 3 to Dsg 1. During  disease 
transition this mechanism dictates the development of Dsg  autoantibodies 
that recognize human skin and lead to expression of cutaneous PV lesions.61    
 
Desmoglein compensation hypothesis: (Fig. 2) 
Pemphigus foliaceus  sera contain only anti desmoglein 1 antibodies 
and cause blisters by interfering with the function of Dsg 1, where there is no 
Dsg 3 to compensate. In the superficial epidermis of skin in early pemphigus 
vulgaris when patients produce only anti Dsg 3 antibodies, separations 
develop deep  in the mucous membrane where Dsg 1  will not compensate for 
loss of Dsg 3 mediated adhesion. Later in the course of the disease when, the 
patient’s serum contains both anti-Dsg 1 and anti-Dsg 3 antibodies the 
function of both Dsgs is compromised and blisters occur in the skin and 
mucous membranes.62                                      
Desmoglein compensation also explains why neonatal pemphigus 
foliaceus is so unusual even though the antidesmoglein 1 antibodies cross the 
placenta. In neonatal skin as opposed to adult skin, desmoglein 3 is co-
expressed with desmoglein 1 in the superficial epidermis.63  
Recently described experiments that explain blister localization in PF on 
the basis of the Dsg compensation hypothesis also suggest that anti-Dsg 
antibodies cause disease by inhibiting Dsg-dependent adhesion. The validity 
of this hypothesis has been confirmed in experiments with PV and PF 
antibodies in normal and Dsg 3null mice. The Dsg compensation hypothesis is 
incompatible with the protease theory of blister formation. If protease were the 
major cause of blister formation in pemphigus then binding of autoantibodies 
to either Dsg 1 or Dsg 3  will not cause protease release and blister formation 
and prevent functional compensation of one by the other.62  
 
Clinical features of pemphigus variants: 
Pemphigus Vulgaris: 
Pemphigus vulgaris, the most common type of pemphigus, 
predominates in middle-aged and elderly Jewish patients and is characterized 
by formation of flaccid blisters and/or erosions. Neonates born to mothers with 
active PV may have similar lesions during the first few months of life.62 
Mucosal dominant PV is characterized clinically by mucosal erosions mainly in 
the oral cavity with minimal skin involvement. Mucocutaneous PV is 
characterized by extensive skin blisters and erosions in addition to the 
mucosal lesions. Cutaneous type PV exists as a rare phenotype of pemphigus. 
This type is clinically characterized by PF-like scaly crusted erosions on the 
skin without mucosal involvement, although the skin lesions can be 
polymorphic, including tense vesicles or blisters in an annular arrangement, or 
eczematous lesions.64 
Pemphigus vegetans is a variant of pemphigus vulgaris. It has been 
subdivided into two groups, the Neumann and the Hallopeau type. The 
Neumann type is characterised by vegetating lesions on the flexures. The 
Hallopeau type is a relatively benign form which may start as vesicles and 
pustules which erode and heal with vegetations.  Extensive fissuring of the 
tongue called ‘cerebriform tongue’ has been classically decribed in pemphigus 
vegetans by Premlatha et al.65 
Pemphigus foliaceus:  
Pemphigus foliaceus, is  a disease of the middle-aged and elderly but 
does not preferentially affect Jews. The most characteristic lesions of PF are 
scaling and crusted plaques on the trunk. In contrast to PV, oral lesions are 
almost never seen in PF. Intact blisters are also uncommon.62 
           Pemphigus erythematosus is a variant of PF with erythematous scaly 
lesions over the nose and cheeks in a butterfly distribution simulating 
cutaneous lupus erythematosus or seborrhoeic dermatitis. Sunlight may 
exacerbate the disease. Oral lesions are rare.10 
           Pemphigus herpetiformis is a variant of pemphigus foliaceus. The 
clinical picture is variable often with coalescent annular or gyrate 
vesiculopustular lesions.66  
Intercellular IgA dermatosis: 
          Two types are distinguished based on the level of pustule formation and 
IgA deposition: the subcorneal pustular dermatosis type and intraepidermal 
neutrophilic type.67 Patients with both types have flaccid vesicles or pustules 
arising on either erythematous or normal skin. The lesions may be pruritic and 
show a circinate or annular configuration with central clearing and evolve to 
crusted or scaly erythematous macules. The sites of predilection are the 
axillae and groins.        
Induced pemphigus: 
The clinical features of drug induced pemphigus may be atypical. The 
initial manifestation may be a non specific erythematous rash. The full-blown 
disease usually presents as scaling and crusting with superficial vesicles and 
blisters. Some cases may present with pemphigus erythematosus-like picture 
with crusting and scaling on the butterfly area of the face. Rarely some cases 
present with classical pemphigus vulgaris. Oral mucosa is involved in 50% of 
cases.68 
Paraneoplastic pemphigus : 
Paraneoplastic pemphigus (PNP) constitutes a distinctive syndrome 
characterized by extensive recalcitrant oral erosions and polymorphic skin 
lesions, that often occur in patients with known neoplasms (especially B-cell 
lymphomas, leukemias, thymomas or Castleman tumors).62 
The transition between PV and PF is a rare medical event.69,70,71  The 
transition from  PF  to PV is less common than that of PV to PF. The 
mechanism of transition remains elusive. One possible mechanism is epitope-
spreading phenomenon which is considered as a primary autoimmune or 
inflammatory process that causes tissue damage by exposing immunologically 
hidden protein to the immune system thereby evoking a secondary 
autoimmune response.72  
 
Diagnosis: 
Cytodiagnosis: 
 Cytological examination using a Tzanck preparation is useful for the 
rapid demonstration of acantholytic epidermal keratinocytes in the blisters of 
pemphigus. A smear is taken from the underside of the roof and from the base 
of an early freshly opened bulla. Giemsa staining is done with subsequent 
rinsing and air drying.73  Since acantholytic keratinocytes are occasionally seen 
in various non acantholytic vesiculobullous or pustular diseases as a result of 
secondary acantholysis, cytologic examination represents merely a preliminary 
test and should not supplant histological examination.28 
Histopathology: 
 Early blisters, preferably small ones, should be selected for biopsy. If no 
recent blister is available an old one may be moved  into the neighbouring skin 
by gentle vertical pressure with a finger. 
Pemphigus vulgaris: 
 The earliest feature may either be eosinophilic spongiosis or more 
commonly spongiosis in the lower epidermis. Acantholysis leads first to the 
formation of clefts and then to blisters in a predominantly suprabasal location. 
The basal keratinocytes though separated from one another remain attached 
to the dermis like a “row of tombstones”. The blister roof consists of the 
remaining intact squamous epithelium. Within the blister cavity are 
acantholytic keratinocytes. Cutaneous type PV has suprabasal acantholysis as 
found in PV. Superficial blistering is occasionally observed.28 
Pemphigus vegetans: 
 In the Neumann type, the early lesions consist of bullae and denuded 
areas that have the same histologic picture as that of pemphigus vulgaris. As 
the lesions age there is formation of villi and verrucous epidermal hyperplasia. 
In the Hallopeau type the early lesions consist of pustules arising on normal 
skin with acantholysis and formation of  small clefts, many in a suprabasal 
location. The clefts are filled with numerous eosinophils and degenerated 
acantholytic epidermal cells. Early lesions may reveal more eosinophilic 
abscesses than in Neumann type.28 
Pemphigus foliaceus: 
 The earliest change consists of acantholysis in the upper dermis,within 
or adjacent to the granular layer, leading to a subcorneal blister in some 
instances. The number of acantholytic keratinocytes is usually small. In the 
setting of a subcorneal blister, dyskeratotic granular keratinocytes are 
diagnostic.28  
Pemphigus herpetiformis: 
 There are diverse histopathological patterns: intraepidermal and 
subcorneal microabscesses, eosinophilic spongiosis or superficial bullae with 
scant acantholytic cells.66 
Pemphigus erythematosus: 
 The light microscopic features are identical to those of pemphigus 
foliaceous.28 
IgA pemphigus: 
 Two patterns are observed that parallel the clinical presentation. In the 
first there are subcorneal vesiculopustules or pustules with minimal 
acantholysis. In the second, intraepidermal vesiculopustules or pustules which 
contain small to moderate number of neutrophils.28 
Drug induced pemphigus: 
 The findings in early lesions are non specific, consisting of spongiosis, 
parakeratosis and a variable dermal infiltrate. Well developed lesions are 
essentially identical to those of pemphigus foliaceous or pemphigus vulgaris. 
Eosinophilic spongiosis may be prominent.28 
Paraneoplastic pemphigus: 
 The principal findings are suprabasal acantholysis with, in addition, 
dyskeratosis. Characteristically there is also a vacuolar interface dermatitis 
with lichenoid inflammation. 28 
Direct immunofluorescence: 
 Currently the diagnosis of pemphigus largely relies on 
immunofluorescence testing utilizing both DIF and IIF. DIF testing is a very 
reliable and sensitive diagnostic test for Pemphigus, in that it demonstrates 
IgG in the squamous intercellular/cell surface areas in upto 95% of cases, 
including early cases and those with very few lesions, and in up to100% of 
cases with active disease.74  It may remain positive, often  for many years after  
the disease has subsided.  Negative DIF findings when patient is in remission 
may be a good prognostic indicator. A study on immunofluorescence in 
pemphigus from North India has demonstrated the value of DIF for a definitive 
diagnosis of pemphigus. However, the authors also felt it important to 
appreciate that immunofluorescence is not a substitute for histopathology, but 
rather complementary to it.15   
 The edge of a blister with intact surrounding normal skin or uninvolved 
skin adjacent to a blister is taken for biopsy. The tissue may be snap frozen or 
transported in Michel’s medium.28 (Table 3) 
Indirect immunofluorescence: 
 Indirect immunofluorescence is a two step procedure used to identify 
circulating autoantibodies to cutaneous or mucosal structures in patients 
serum.75 Reproducible results can be obtained only if the substrate is 
appropriately selected with respect to the nature of the circulating antibodies. 
The best results are obtained by using normal human skin from unexposed 
sites. The other substrates used are monkey oesophagus, guinea pig lip and 
guinea pig oesophagus. In case of paraneoplastic pemphigus rat bladder 
epithelium is found to be an excellent substrate.76   With serial dilutions of the 
patients serum, the highest dilution that results in fluorescence is taken as the 
titre. Although the titre generally correlates with disease activity, a single titre 
cannot be used as a basis for adjusting the drug dosage. Patients in remission 
but with persistent antibodies are likely to develop a relapse on cessation of 
therapy. A two fold rise in the titre may indicate an impending relapse. 
Continued negative titres for more than one month are good prognostic 
indicators of prolonged remission.75 
Immunoblotting and Immunoprecipitation: 
 Although Western immunoblotting and immunoprecipitation can be 
used to identify the target antigen in cases of pemphigus these are both time 
consuming, qualitative techniques, impractical for routine screening of large 
samples.5     
 Immunoblotting and immunoprecipitation studies have demonstrated 
that the target molecules of pemphigus are, a 130-kDa glycoprotein in PV and 
a 160 kDa glycoprotein in PF.6  Hashimoto et al77 studied 18 cases of 
pemphigus characterized by diagnostic difficulty and suggested that 
immunoblot analysis for pemphigus antigens is a reliable tool for the diagnosis 
of pemphigus.77   
 
Desmoglein assay: 
 The desmoglein proteins Dsg 3 and Dsg 1 have been identified as the 
antigens in PV and PF  respectively. cDNA cloning of  the 130 kDa 
glycoprotein and the 160 kDa glycoprotein revealed them to be members of 
the desmoglein subfamily of the cadherin supergene family. For PV the 
autoantigen was determined to be Dsg 3, whereas the PF autoantigen was 
found to be Dsg 1. Ishii et al6 produced recombinant pemphigus antigens 
using a baculovirus expression system, PV Ig for PV antigen and PF Ig for PF 
antigen. These molecules were designed as a chimeric molecule which 
contains the entire extracellular domain of Dsg 3 and Dsg 1 fused with the 
constant region of human IgG1. Further, utilizing the recombinant Dsg 1 and 
Dsg 3 they developed a quantitative, sensitive and specific ELISA for the 
detection of antibodies directed against these antigens.6  
The demonstration that large quantities of extracellular domain of PV 
antigen with the proper conformation can be produced by baculovirus has 
several important implications. From a clinical point of view ELISA using PV 
Ig-Sf9 as an antigen source would be a sensitive and specific diagnostic tool. 
Scores of this ELISA should correlate even better with disease activity than 
currently used immunoflourescence tests with normal skin because IgG titres 
can only be measured against the pathogenic extracellular domain of PV 
antigen. Furthermore as a new type of treatment, antigen specific 
plasmapheresis with a PVIg-Sf9 column could be developed which could 
specifically remove pathogenic IgG against PV antigens from patient’s 
circulation with minimal side effects. From a biological point of view this 
recombinant protein would be valuable to study adhesion function of PV 
antigen in cultured keratinocytes and also to do fine epitope mapping of PV 
antigen.44 
 
Usefulness of desmoglein ELISA as a diagnostic test: 
The first report of ELISA for diagnosis in pemphigus found it to be 
highly sensitive and specific. Ishii et al6 studied 49 PV patients and 46 PF 
patients. The sensitivity and specificity of Dsg 3 ELISA were 94% and 96%, 
the sensitivity and specificity of Dsg1 ELISA were 96% and 96% respectively. 
         Lenz et al78 in a study from Vienna  produced recombinant Dsg (rDsg) 3 
protein in their laboratory and validated the test among their patients and 
expanded the published results by testing additional diseases groups including 
other bullous dermatoses or autoimmune connective tissue diseases. They 
found a sensitivity of 93% which increased to 98% when IIF negative serum 
samples were excluded indicating that both tests have a similar sensitivity. 
They also established a specificity of 93%. 
 Amagai et al7  further evaluated the practical application of these 
ELISA tests for the serological diagnosis of PV and PF with a large number of 
serum samples collected from four different dermatological institutions in 
Japan. They used PF, PV and normal sera to analyse the sensitivity and 
specificity using ROC curves. The cut-off values for achieving highest 
sensitivity and specificity were determined to be 11.0 for Dsg 1 and 10.0 for 
Dsg 3 ELISA. However `with these cut-off values a small number of sera 
obtained from controls fell into the positive zone. They set up a grey zone 
which was above the cut-off value and below the kits cut-off of 20.0. They  
then determined the sensitivity and specificity of Dsg1 to be 97.9% and 98.9% 
respectively and Dsg 3 to be 97.5% and 97.8% respectively.7 
 Harman et al5 have critically evaluated two ELISA’s for the detection 
of antibodies to the major pemphigus antigens, demoglein 1 and 3. They 
found that when serum samples taken from untreated cases were examined 
both the Dsg 1 and Dsg 3 ELISA showed a sensitivity of 100% for the 
diagnosis of PV and PF. When patients on systemic treatment were included, 
the sensitivity dropped to 95% in PV and 92% in PF but the figures compared 
favourably to  the overall sensitivity of IIF which was 79% in PV and 84% in PF. 
The high sensitivity of ELISA was matched by a high specificity of 98% or 
more. Dsg 3 autoantibodies were not detected in any of the PF subjects 
whereas Dsg 1 autoantibodies were detected in 60% of PV subjects. Using a 
combination of Dsg 1 and Dsg 3 ELISA , PV and PF could be distinguished.  
 Bhol K et al79 have also evaluated the use of recombinant 
pemphigus vulgaris antigen in development of ELISA and immunoblot assays 
to detect pemphigus vulgaris autoantibodies and found ELISA and immunoblot 
titres in all patients to be higher than with conventionally used IIF assay. They 
concluded that ELISA and immunoblotting are superior to IIF in evaluating 
antibody levels in pemphigus patients and that ELISA is more practical and 
preferable than immunoblot in routine clinical use.79 
 A recent study from India evaluated Dsg ELISA in Indian patients 
with pemphigus vulgaris. Sharma et al8 studied twenty seven active PV 
patients and 26 controls. They found the sensitivity and specificity of  ELISA 
for anti-Dsg 1 in the diagnosis  of PV to be 96.3% and 92.3%, respectively. For 
anti-Dsg 3 they were 85.2% and 100%, respectively. 8 
              Amagai et al7 propose that Dsg 3 positivity irrespective of Dsg 1  is 
diagnostic of PV, and Dsg 1 positivity with  negative Dsg 3 is diagnostic of 
PF(Table 4). In their study of 81 PV and 48 PF sera, serodiagnosis by ELISA 
matched the clinical diagnosis in 86.8 % of PV and PF cases. However these 
criteria applied only to patients with active disease. They observed that sera 
from some PV patients in remission showed reactivity only against Dsg 1 and 
they speculate that these patients could have had both Dsg 1 and 3 
autoantibodies when the disease was active, but as the disease subsided only 
anti Dsg 1 antibodies stayed positive.7 
 Severity of cutaneous and oral pemphigus in relation to Dsg 1 and Dsg  3 
antibody titres: 
The apparent correlation of pemphigus antibody titres with severity of 
disease was first suggested in early studies on the specificity of the 
pemphigus antibody.80 This initial impression has been confirmed repeatedly 
in several series of patients by studying antibody titre by IIF in subsequent 
years. 
            Ishii et al6 demonstrated that PV patients with skin involvement tend to 
have higher anti-Dsg 1 IgG titres than those with predominant oral lesions.6    
           Harman et al81 in a study of 104 patients have found that there was a 
clear relationship between the clinical presentation of disease and the Dsg 
autoantibody profile.81 
            Kumar et al9 attempted to correlate the extent of skin and mucosal 
involvement with independent values of Dsg 1 and Dsg 3 ELISA. They used a 
simple arbitrary scoring system to grade the severity of skin or mucosal 
disease.  Although a wide range of values were obtained the general trend 
was that Dsg 3 levels were higher in patients with extensive oral mucosal 
involvement  than those with mild or no mucosal involvement. There was a 
direct relationship between severity of skin involvement and  levels of Dsg 1 
antibodies. Forty four patients were analysed using ELISA. A statistically 
significant correlation was seen between increase in Dsg 3 antibody titres with 
severity of oral involvement, and in DsG 1 titres with severity of skin disease in 
both PV and PF  patients. For Dsg 1 ELISA,  5 of 6 PF patients (83.3%) and  
23 of 38 (60.52%) PV patients were above cut off values. For Dsg 3 ELISA, 31 
of 38 (81.57%) PV patients and 1 of 6 (16.6%) PF patients exceeded the cut 
off value.9 
           Ding et al40 showed that mucosal and mucocutaneous pemphigus 
vulgaris show distinct antibody profiles. 
            Sharma et al8  found that though the different morphological types 
could not be differentiated  on the basis of antibody profile, they were able to 
demonstrate a direct correlation between anti-Dsg 3 titres and severity of oral 
disease and also between anti–Dsg 1 titres and  severity of cutaneous disease.     
Amagai et al39 showed that there was a difference in antibody profile among 
mucosal dominant PV, mucocutaneous PV and PF and that the clinical 
phenotype is defined by the antibody profile.  
 However Jamora et al82 have reported that though in general, patients 
with PV and only oral lesions have anti-bodies against  Dsg 3, and those with 
skin lesions have, in addition, antibodies to Dsg 1, their results did not support 
the hypothesis that the sole determinant of lesion location in PV is the profile 
of autoantibodies against Dsg. This was because a significant minority of 
patients did not have the PV phenotype predicted by their antibody profile.82 
Despite the overall relationship between Dsg 1 antibodies and skin severity 
and between Dsg 3 antibodies and oral severity, Harman et al81 found a wide 
range of values within each severity score. They speculate that since 
pemphigus sera target multiple epitopes on both Dsg 1 and Dsg 3 molecules, 
it is possible that cases with minimal disease but high antibody  levels may 
have a high proportion of non pathogenic antibodies either by virtue of their 
subclass or perhaps because they bind to epitopes that do not result in 
disease triggering.  An alternative explanation they propose is that treatment 
may have dampened pathogenic mechanisms triggered by antibody binding in 
these cases. In cases with low ELISA values but active disease, they suggest 
it is possible that the serum contains pathogenic antibodies to non desmoglein 
molecules as demonstrated in other studies of pemphigus sera or to epitopes 
on the intracellular domain of Dsg 1 or Dsg 3 which would be undetectable to 
ELISA.81 
           Harman et al83 suggest that patients who are Dsg 3+/Dsg 1- at 
presentation will not necessarily develop Dsg 1 antibodies while Dsg 3+/Dsg 
1+ patients are at risk of developing a more severe phenotype with extensive 
cutaneous ulceration.83 
Desmoglein ELISA to monitor disease activity: 
 Recombinant ELISAs have been shown to be useful for monitoring 
disease activity.6,7  Ishii et al6 showed that Dsg 1 and Dsg 3 ELISA scores 
showed parallel fluctuation with disease activity along the time course. 
Utilisation of ELISA seemed to be superior to IIF to assess antibody level, as 
routine IIF missed some increases in the level of specific antibody that were 
picked by ELISA.6 
               Amagai et al7 also used ELISA to quantify individual levels of 
antibodies against Dsg 1 and Dsg 3 and examined their correlation with the 
progression of disease activity. In three of the patients studied, the respective 
Dsg 1 and Dsg 3 ELISA scores showed parallel fluctuation with disease 
activity along the time course. These observations suggest that ELISA’s will be 
a valuable tool to measure disease activity.  ELISA scores may also be useful 
to plan tapering schedules of corticosteroids and to predict flares or relapses 
by detecting increase in antibodies before clinical evidence of disease flares 
are noticed.7 
 However in  some patients high antibody index values in ELISA did 
not necessarily parallel disease activity. Cheng SW et al84 have shown that 
index values obtained with appropriately diluted high titre sera do reflect 
disease activity. They suggest that in practical terms  when  diagnostic 
laboratories receive high titre sera, dilutions of 1:1600 in Dsg 1 or Dsg 3 
ELISA should be used and if the index value is still higher than 120, further 
dilutions may be required. This is because ELISA is based on an enzyme 
reaction sera  containing high titre antibodies and can reach a plateau or 
saturation level and thus yielding scores or index values which are 
artefactually lower than they should be.84  
Numerous exceptions have been noted in the relationship of disease 
activity to antibody titre and several authors remain unconvinced of the clinical 
usefulness of sequential titre as a guide to therapy. Prolonged elevation of titre 
after clinical improvement, a lag period in the fall of titre by six to eight weeks 
and failure of the titre to fluctuate with the clinical course, are some of the 
problems encountered in observing serial titres clinically. If a direct relationship 
of sequential antibody titre to disease activity exists in a predictable manner, 
this would indeed be a valuable clinical guide in the management of 
pemphigus. Though a rough correlation of high disease activity with high titre 
and low disease activity with low titres has been demonstrated in literature, it 
is the two fold change in titre that is meaningful and the timing of such a 
change that is clinically important.80 
Desmoglein profiles of the rarer variants of pemphigus : 
In cutaneous pemphigus both anti-Dsg 1 and anti-Dsg 3 IgG antibodies 
are detected with a tendency towards higher titre of anti-Dsg 1 IgG than of  
anti-Dsg 3 IgG.64 
The target antigen for pemphigus herpetiformis is most often Dsg 1. In 
some cases the autoantibodies are directed to multiple epidermal antigens or 
to Dsg 3.66,85 
Anti-Dsg 1 antibodies have been detected in pemphigus 
erythematosus.86  
Desmogleins are recognized by IgA antibodies in a few patients with 
IgA pemphigus.54 
 Anti-Dsg 1 antibodies have been reported in drug induced 
pemphigus. ELISA scores for anti-desmoglein 1 antibodies  also revealed a 
surprisingly rapid decline when the drug was discontinued.87  Korman et al88 
have reported patients with drug-induced pemphigus foliaceus having 
circulating autoantibodies that are directed against the pemphigus foliaceus 
antigen complex  and  a patient with drug-induced pemphigus vulgaris  who 
had circulating autoantibodies that were directed against the pemphigus 
vulgaris antigen complex. 
 Patients with paraneoplastic pemphigus raise antibodies against 
multiple antigens including members of the plakin family as well as 
desmogleins.89,90 Studies have shown that the association between clinical 
phenotype and anti-desmoglein autoantibody profile in PNP is not as clear as 
that in classic pemphigus. 91 
Advantages of  ELISA 
1)  A major advantage of ELISA is the selective detection of antibodies 
against extracellular and conformational epitopes of desmoglein which 
include most pathogenic antibodies in patients with PV. In contrast 
conventional IIF testing may also identify a variety of antibodies against 
protein of the extracellular matrix. Indirect immunoflourescence may 
also fail to distinguish between antibodies directed against the 
intracellular portion of Dsg 3, antibodies against Dsg 1 or desmocollins 
or other ICS constituents. 
2)  Determination of antibody titres by IIF analysis requires serial dilutions 
of serial samples, is subjective, and requires an experienced examiner. 
A potential advantage of ELISA over IIF is that the process can be fully 
automated and that an objective optical density value is obtained at a 
single dilution of 1:10000. 
3)  ELISA allows estimation of pemphigus antibody levels similar to IIF. 
This aspect may be of importance as antibody can parallel clinical 
course. 
  Dsg 3 ELISA studies have shown that increase in ELISA values 
occurred earlier and were more pronounced when compared to IIF 
titres. This may reflect a higher sensitivity of ELISA in specifically 
detecting pathogenic anti-Dsg 3 antibodies which may be helpful in 
monitoring the clinical course  and for adjustment/discontinuation of 
immunosuppressive therapy. Thus far the most reliable indicator of PV 
remission seems to be a negative DIF result requiring repeated skin 
biopsies. Further investigation will determine whether a negative Dsg 3 
ELISA obtained during clinical remission is a sensitive indicator  to 
predict if disease  will stay in remission following cessation of therapy.78 
4)  Desmoglein  ELISA compared with IIF does not require a skilled 
observer and is a simple test to perform. Moreover it is able to 
differentiate PV from PF.92 
5)  In cases where IIF was negative,  nuclear or cytoplasmic fluorescence 
most likely masked and interfered with the detection of intercellular 
antibodies, and ELISA is particularly useful in this subset of patients. 
Also in one of the cases where IIF had been negative, it was later 
positive after a lag period of five months, suggesting that ELISA is more 
sensitive in the early stages of the disease.92 
 
Limitations of ELISA: 
Limitations of ELISA have come to light as a result of comparing results 
with IIF. 
1. The first limitation is that ELISAs are not quantitative at high antibody 
titre. The probable explanation for the plateau in ELISA which results at 
a high antibody titre is that   a limited amount of Dsg 1 and 3 antigen is 
coated to the ELISA plates and that this becomes saturated in the 
presence of high levels of Dsg 1 or 3 antibodies. 
2. The second limitation is that there is a wide variation in the results of  
ELISA in sera that have identical levels  of  antibodies  by IIF assays.  
The cause for this variation is not known. Possibly it reflects the                          
presence of antibodies against intercellular antigens other than Dsg 1 
and 3 in patients with pemphigus.93 
 
 
The significance of the presence of PV-IgG in the sera of healthy family 
members and the reason why these carriers do not develop clinical symptoms 
of the disease are unknown. One possible explanation is that the total quantity 
of pathogenic PV-IgG in the sera of carriers is low and therefore is usually 
significant for binding the antigen sites and causing acantholysis but that 
exposure to other factors, such as infections or drugs, may trigger onset of the 
disease. Another possibility is a difference in the circulating PV-IgG 
subclasses between the affected patients and their clinically unaffected but 
antibody positive relatives.94 
     Production of autoantibodies in PV is polyclonal and in PV patients 
with active disease most autoantibodies are of the IgG4 subclass. Patients in 
remission have mainly autoantibodies of the IgG1 subtype while healthy 
relatives of PV patients and healthy carriers of PV prevalent HLA class II 
alleles appear to have low levels of  Dsg 3 reactive IgG.95 
      Veldman C et al96 suggest that immunological tolerance against Dsg 
3, the autoantigen of PV may be, at least partly, mediated by Dsg 3-specific 
type 1 T regulatory cells. This provides an explanation as to why B cell 
tolerance against Dsg 3 exists in healthy individuals who carry autoaggressive 
T cells reactive to Dsg 3 epitopes identical to those recognized by T cells from 
the PV patients. Thus, Dsg 3-responsive type 1 T regulatory cells may 
represent an ideal tool to therapeutically restore Dsg 3-specific immune 
tolerance in PV.98 
 There are several reports which describe the coexistence of 
features of both PV and PF in the same patient or the transformation of PF to 
PV and vice versa on an extended period of time.71,97  Sami et al98 suggest that 
in PF,for those patients who do not respond to conventional therapy in a 
reasonable time serological evaluation for both antidesmoglein 1 and 3 
antibodies may provide an identification of this group of patients. 
            Spaeth  et al99 have studied IgG, IgA  and IgE autoantibodies  against 
the ectodomain of desmoglein  3 in active pemphigus vulgaris and conclude 
that by immunoblot analysis utilising a baculovirus –encoded recombinant 
form of Dsg 3 encompassing its entire extracellular domain autoantibodies of 
the IgG4, IgG1, IgA and IgE  subclasses were detected in both acute onset  
and chronic active PV while IgG1 and IgG4 were the only subtypes of 
autoantibodies present in sera of patients in remission. The detection of Dsg 3 
reactive IgA and occasionally IgE in active PV was a novel finding which could 
be exploited as a predictive and prognostic marker.99 
Patients with bullous diseases present physicians with formidable 
challenges. Precise diagnoses are usually possible using a combination of 
clinical, histological, immunohistological and immunochemical criteria. 
Advancements in our understanding of the mechanisms that regulate 
formation of anti-Dsg antibodies may facilitate development of more specific 
interventions. ELISAs using the recombinant pemphigus antigens when used 
together provide a sensitive, specific and quantitative diagnostic tool for the 
evaluation of patients with pemphigus. This new diagnostic tool will be useful 
not only for clinical application but also for the more precise characterization  
of the antibody response in patients with pemphigus and for understanding 
fundamental immunopathologic mechanisms of pemphigus. The challenge for 
the future is to develop more specific less toxic therapies based on better 
understanding of the immunoregulatory mechanisms that allow autoantibody 
production.62 
 MATERIALS AND METHODS 
Study Design :  Cross sectional study 
Setting: The study was conducted in the Outpatient Department of 
Dermatology, Venereology and Leprosy, Christian Medical College, a tertiary 
care hospital in South India 
Duration of study:  The study was conducted between March 2005 and July 
2006. 
Study population:  All patients with  acquired immunobullous disorders, 
diseases targeting desmogleins or having conditions where antibodies mimic 
or show in vitro deposition in stratified squamous epithelium in the absence of 
pemphigus were eligible for inclusion into the study. 
Inclusion criteria: 
Patients :  
All consecutive patients with pemphigus who consented for the study 
and in whom the diagnosis had been confirmed by histopathology and direct 
immunoflourescence were included. 
Controls: 
1)  Patients with acquired immunobullous disorders other than pemphigus 
(eg. bullous pemphigoid, epidermolysis bullosa aquisita or chronic 
bullous dermatosis of childhood) who consented for the study and who 
had been diagnosed by clinical features, histopathology and DIF were 
included as in other studies. 
2)  Patients with diseases targeting desmogleins like bullous impetigo or  
staphylococcal scalded skin syndrome (SSSS) or having conditions 
where antibodies mimic or show in vitro deposition in stratified 
squamous epithelium in the absence of pemphigus like toxic epidermal 
necrolysis (TEN), who consented for the study and who had been 
diagnosed by clinical features, gram stain, histopathology or DIF as 
appropriate were included.  
Exclusion criteria: 
Patients 
Patients not willing for the study. 
Controls  
Patients not willing for the study   
Methodology: 
Patients 
All pemphigus patients who conformed to the inclusion criteria were 
examined by the principal investigator after written informed consent was 
taken (annexure I). The details regarding duration of disease, sites of 
involvement, duration and type of treatment, relapses and extent of lesions 
were recorded in a proforma (annexure II). Details of diagnostic tests were 
recorded. Patients were categorized into the various clinical types based on 
the clinical features, histopathology and DIF. The severity of lesions were 
assessed clinically based on the scoring system used by Harman et al.81 Skin 
lesions and oral lesions were scored separately and recorded.  
Oral lesions were scored as  
0 - Quiescent 
1 - Minor activity ( upto 3 erosions ) 
2 - Moderate activity (4 -10 erosions or generalized desquamative   
   gingivitis ) 
3 - Severe ( >10 discrete erosions or extensive confluent erosions or    
generalized desquamative gingivitis with discrete erosions at other oral     
sites ) 
Skin lesions were scored as 
0 -  Quiescent 
1 -  Minor activity ( < 5 discrete lesions) 
2 -  Moderate activity ( 5-20 discrete lesions) 
3 -  Severe (  > 20 discrete lesions or extensive confluent areas of eroded 
skin.) 
Patients with pemphigus were also divided into 3 categories : acute 
onset, chronic active and remittent as by Spaeth et al.99  The same criteria  
was applied to cutaneous lesions as well. 
Acute onset was defined as the de novo development of blisters or 
erosions on previously unaffected mucosal or cutaneous surfaces. None of the 
patients would have received immunosuppressive therapy at the time the 
serum was obtained.  
Chronic active disease was defined as expansion/persistence of 
existing blisters or erosions on mucosal or cutaneous surfaces.  Patient could 
have already received immunosuppressive therapy. 
Patients with remittent disease had not experienced mucosal or 
cutaneous blisters/erosions during the two or more months prior to study 
Sera  were obtained from pemphigus patients when the diagnosis was 
established and patients were scored.  
Controls: 
Thirty six consecutive controls who conformed to the inclusion criteria 
were examined by the principal investigator after written informed consent was 
taken (annexure I). The details regarding duration of disease, sites of 
involvement, duration and type of treatment   were recorded in a proforma 
(annexure III). Details of diagnostic tests were recorded. Sera were obtained 
when the diagnosis was established. 
 
 
All sera were coded and the investigator performing the ELISAs was 
blinded. Sera were stored at -70°C until assays were performed. The ELISAs 
were performed using kits purchased from Medical and Biological laboratories 
Co.Ltd., Nagoya, Japan.  
Principle of the test: 
The test measures, by ELISA, the Dsg antibodies present in the serum. 
Sera are added to separate microwells coated with Dsg 1 or Dsg 3 allowing 
anti-Dsg 1 or anti-Dsg 3 antibodies respectively to react with the immobilized 
antigen (sample incubation). After wash, to remove any unbound serum 
proteins, horseradish peroxidase conjugated anti-human IgG monoclonal 
antibody is added and incubated (conjugate incubation). Following another 
washing step, the peroxidase substrate is added and incubated for an 
additional period of time (substrate incubation). Acid solution is then added to 
each well to terminate the enzyme reaction and to stabilize the color 
development. The assay can be quantified by measuring the reaction 
photometrically.  
Brief assay procedure :  
(Sample incubation)  Add 100µl of diluted sample to each well of the microwell 
plate (20-25° C) 60 min          
                                      Wash 
                                        
(Conjugate incubation) Add 100µl of conjugate solution to each well  
 (20-25° C) 60 min            
                                    Wash 
                                         
(Substrate incubation) Add 100µl of substrate to each well  
(20-25° C) 30 min         
                                     Add 100µl of stop solution to each well 
                                        
                               Read absorbance and interpret result. 
Unit value(U/ml)=(Optical density(OD) of tested serum-OD of negative control)X 100 
                                    (OD of positive control- OD of negative control) 
Both positive and negative controls provided in the kit were included in every 
plate.  
For all analysis the cut –off values given in the kit were taken as standard. 
The cut-off values were applied to patients and controls to determine 
the sensitivity and specificity of ELISA estimation of Dsg antibodies in 
pemphigus. Dsg 1 values were determined from PF patients and Dsg 3 values 
were determined from mucocutaneous, cutaneous and mucosal PV patients. 
The sensitivity and specificity of ELISA estimation of Dsg 1 and 3 antibodies in 
differentiating PV and PF using criteria proposed by Amagai et al were also 
studied.7 
We also generated cut off values for the local population as the kit was 
manufactured elsewhere. The Receiver-operating-characteristic (ROC) 
analysis was performed to determine cut-off values for Dsg 1 and Dsg 3 
ELISAs. The sensitivity and specificity were plotted when different scores were 
used as cut-off values and the one which gave the highest score for the sum 
of sensitivity (%) and specificity (%) was determined to be the cut off value for 
the population studied. For this analysis, data obtained with PF sera and  
controls were used for Dsg 1 ELISA and data obtained with PV sera and 
controls were used for Dsg 3 ELISA .7 
Correlation of  Dsg 1 and Dsg 3 titres with mucosal and cutaneous 
involvement, category of disease, duration of disease, number of relapses and 
severity of disease were investigated. The prevalence of Dsg antibodies in the 
various clinical variants of pemphigus included in the study were also 
investigated. 
The study was approved by the institutional research committee. 
Sample size: 
The sample size was calculated using the formula       1.962 x (p.q) 
                                                                                                d2 
A minimum of 36 patients and 36 controls were required to validate 
ELISA estimation of Dsg 1 and Dsg 3 antibodies as a diagnostic test for 
pemphigus with a sensitivity and specificity of  90% and confidence intervals of  
80-100. 
 
Statistical analysis: 
The statistical analysis was performed using SPSS 11.0 for Windows. 
The optimum cut off values of Desmoglein 1 and 3   ELISA  for the population 
studied were determined using the ROC (Receiver Operating Characteristic) 
Curve approach. 
Associations between categorical variables were analyzed using the 
Chi-square tests. 
Relationships between continuous variables were assessed using 
Pearson’s product moment correlation with scatter plots as diagrammatic 
representation of the correlation. Relationship between continuous and 
categorical variables were analysed using ‘t’- tests and error bars were 
provided for a graphical representation to see how the means of the 
continuous variables were different across different levels of the categorical 
variables. 
 
RESULTS 
Study population: 
Distribution of cases and controls in the study population:  
Seventy five patients were enrolled into the study between March 2005 
and July 2006. There were 39 (52%) pemphigus patients and 36 (48%) 
controls. 
 Age and Sex distribution:   
 The mean age of the study population was 37 years with a SD of ± 
20.68. The oldest being 75 years and the youngest being 1 year old. There 
were 36 males (48%) and 39 females (52%).  Male to female ratio was 1:1.08.  
Profile of patients with pemphigus: 
Age distribution: 
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 The mean age of pemphigus patients was 43.21 years with a SD of ± 
13.89. The youngest was 17 years and the oldest was 73 years.(Fig.3) The 
majority of patients were in the age group of 30 – 59 years. 
Figure 3:  Age distribution of patients with pemphigus 
  
 
Gender distribution of patients: 
 There were 23 (58.97%) females and 16 (41.03%) males.  The male to 
female ratio was 1: 1.43.  
 
 
Duration of lesions: 
The mean duration of lesions at presentation was 21.96 months with a 
SD of ±23.34. The range was 0.6 to 108 months. 
 
 
Presence of oral and skin lesions: 
Of the 39 patients, 32 (82.05%) had skin lesions and 27 (69.23%) had 
oral lesions at presentation. Twenty patients (51.2%) had both oral and skin 
lesions. 
 
 
Distribution of acute onset and chronic active patients: 
 There were 8 (20.51%) patients with acute onset disease and 31 
(79.48%) patients with chronic active disease. There were no patients with 
remittent disease.   
 Clinical variants of  pemphigus patients 
 
Among the 39 pemphigus patients, there were 24 patients with 
mucocutaneous PV and 2 patients each with cutaneous pemphigus and 
mucosal pemphigus. Seven patients had PF. One patient each had 
pemphigus vegetans, pemphigus herpetiformis, IgA pemphigus and 
paraneoplastic pemphigus. (Fig. 4,5,6,7,8). 
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Figure 6: Clinical variants of pemphigus patients 
 Severity scoring of skin lesions 
 
 
 
3210
25
20
15
10
5
0
N
um
be
r o
f p
at
ie
nt
s
21
5
6
7
Skin scores   
 
 
Seven patients did not have any active disease in the skin. 
Twenty one patients had the maximum skin severity score of 
three. (Fig.9) 
 
 
 
 
Figure 9: Severity scores of pemphigus patients with skin 
lesions 
  
Severity scoring of oral lesions 
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 Twelve patients did not have active disease of the oral mucosa. Five, 
twelve and ten patients had an oral severity score of one, two and three 
respectively. (Fig.12). 
  In all patients the diagnosis was based on clinical features, 
histopathology and DIF findings.(Fig. 10,11,13,14) 
  
 
Figure 12: Severity scores of pemphigus patients with oral 
lesions 
Controls: 
Age distribution of controls: 
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 The mean age of controls was 30.33 years with a SD of ± 24.63. The 
range was 1 to 75 years. (Fig.15) 
 
 
Gender distribution 
 There were 16 (44.44%) males and 20 (55.56%) females. The male to 
female ratio was 1:1.25  
 
 
 
Figure 15:  Age distribution of controls 
Clinical profile of controls  
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CBDC - Chronic bullous dermatosis of childhood 
SSSS - Staphylococcal scalded skin syndrome 
SJS - Stevens Johnson syndrome 
TEN - Toxic epidermal necrolysis 
 
Among the controls nine patients had bullous pemphigoid, one patient each 
had chronic bullous dermatosis of childhood and epidermolysis bullosa 
acquisita. There were 13 patients with bullous impetigo, 7 patients with SJS 
/TEN or TEN and 2 patients with SSSS. (Fig.16,17,18) 
Figure 18:  Clinical profile of controls 
Validity of  ELISA estimation of desmoglein 1 and 3 antibodies 
in the diagnosis of pemphigus. (Fig 19,20,21) 
 
     Diagnosis Desmoglein  positive Desmoglein negative Total 
Pemphigus Vulgaris             23                5 28 
Control             0                  36    36     
The sensitivity of the test was determined to be 82.14%  and the specificity 
was 100%. (Table 5) 
 
     Diagnosis Desmoglein  positive Desmoglein negative     Total
Pemphigus 
foliaceous 
            7              0          7 
Control             1                  35         36  
The sensitivity of the test was determined to be  100% and the specificity was 
97.2%. (Table 6)  
 
Application of diagnostic criteria for pemphigus vulgaris and pemphigus 
foliaceous proposed by Amagai et al (Table 4)  
All of the 7 PF sera were positive against Dsg1 but negative for Dsg 3.Of the 
28  PV sera 23 were positive against DsG 3 (82.14%). Applying these values 
to the diagnostic criteria proposed by Amagai et al7 the serodiagnosis was 
consistent with the diagnosis in all (100%) of PF patients and (82.14%) of the 
PV patients.  
Table 5: Sensitivity and specificity of ELISA estimation of Dsg 3 
Table 6: Sensitivity and specificity of ELISA estimation of Dsg 1 
Determination of desmoglein 1 and 3 cut-off for local  
population 
 
 
 
 
 
 
 
 
 
 
 
 The ROC analysis using PF sera and normal control for Dsg 1 ELISA 
determined  a cut-off value of 17.79 with a sensitivity  of  100%  and specificity 
of  97.22%.(Fig. 22)  
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 The ROC analysis using PV sera and normal control for Dsg 3 ELISA 
determined  a cut-off value of 28.91 with a sensitivity  of  88.46%  and 
specificity of  100%. (Fig. 23)  
ROC Curve
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Figure  22:  ROC curve for desmoglein 1  
Figure  23:  ROC curve for desmoglein 3 
Prevalence of desmoglein 1 and 3 in patients with mucosal, 
cutaneous and mucocutaneous involvement 
 
Dsg 3  was positive in  25 (92.5 %) of   the 27 patients with oral lesions. Dsg 3 
was positive in one patient who did not have oral lesions. (Table 7) 
 
       Skin lesions    Dsg 1 positive     Dsg1 negative     Total 
           Present            25             7         32 
           Absent             2             5           7 
            Total            27            12         39 
 
Dsg 1 was positive in  25(78.12%) of the 32 patients with skin lesions. Dsg 1 
was positive in 2 patients without skin lesions. (Table 8)  
 
Skin  and  Oral  
Lesions                       
  Dsg 1 and 3 
positive           
 Dsg1 and/or 3 
negative 
    Total 
           Present            14               6 *       20   
 Absent              2              17           19    
            Total            16               23       39    
* 6 Dsg 1 negative  
Dsg 1 and 3 were  positive in 14 (70% )  of  the 20 patients with oral and skin 
lesions. (Table 9)  
        Oral  lesions    Dsg 3 positive     Dsg 3 negative     Total 
           Present            25               2         27   
             Absent             1              11            12    
            Total           26               13       39    
Table  7:  Prevalence of  desmoglein  3 in patients with oral lesions
Table 8:  Prevalence of  desmoglein 1 in patients with skin lesions
Table  9:  Prevalence of  desmoglein 1 and 3 in patients with oral and 
skin lesions
Correlation of desmoglein 1 and 3 titres with oral and skin 
lesions 
                                                  
Skin lesion  No of patients Dsg 1 U/ml 
Mean ± SD 
Dsg 3 U/ml 
Mean ± SD 
     Present           32 88.21 ± 80.05 120.58 ± 98.64 
     Absent            7 16.18 ± 20.18 114.56 ± 107.84 
     p value   0.025  0.886 
 
The mean  Dsg 1 titres of patients with skin lesions were significantly higher 
than those of patients without skin lesions.(p=0.025).There was no such 
correlation between oral lesions and Dsg 1 titres.(p=0.886) (Table 10) 
 
 
Oral lesion  No of patients Dsg 3 U/ml 
Mean ± SD 
Dsg 1 U/ml 
Mean ± SD 
     Present      27   166.83 ± 79.98 63.35 ± 71.54 
     Absent     12        13.01 ± 28.20 102.14 ± 88.07 
     p value   0.000  0.154 
 
The mean  Dsg 3 titres of patients with oral lesions were significantly higher 
than those of  patients without oral lesions(p=0.000).There was no such 
correlation between skin lesions and Dsg 3 titres(p=0.886). (Table 11) 
Table 10:  Correlation of desmoglein 1and 3 titres with skin lesions   
Table 11:  Correlation of desmoglein 1 and 3 titres with oral lesions 
  
 
Correlation of desmoglein titres with acute onset and chronic 
active disease. 
 
 
 
Category Acute onset  Chronic active P value 
Dsg 1  55.14 ± 85.34 80.48 ± 76.55 0.313 
Dsg 3  129.54 ± 111.58 116.91 ± 97.20 0.626 
 
In  the acute onset disease, the  Dsg 1 mean value was 55.14 with SD ±  
85.34 when compared to a mean value of  80.48 with SD ± 76.55 in chronic 
active disease(p = 0 .313). The  Dsg 3  mean value in acute onset disease 
was 129.54 with a SD ± 111.58 while in chronic active disease the mean value 
was 116.91 with a SD ± 97.20( p value = 0.626). There was no significant 
difference in Dsg 1 or Dsg 3 titres of patients with acute onset and chronic 
active disease. (Table 12) 
 
 
 
Table 12:   Correlation of desmoglein titres with acute onset and chronic 
active disease 
Correlation of Desmoglein titres with duration of disease 
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Using the Pearsons correlation coefficient  to correlate Dsg 1 titres with 
duration of disease r value was found to be  -0.242 and p value was 0.137.       
(Fig. 24 )  
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Using the Pearsons correlation coefficient  to correlate Dsg 3 titres with 
duration of disease r value was found to be  0.048 and p value was .773           
(Fig 25).There  was no significant change in Dsg 1 or 3 antibody titres with 
respect to duration of  disease. 
Figure  24:  Correlation of desmoglein 1 titres with 
duration of disease 
Figure 25:  Correlation of desmoglein 3 titres with duration of disease 
Correlation of skin severity scores with desmoglein 1 titres  
 
 
      Score    
 
No of patients  Mean titre( U/ml) Standard 
deviation 
          0             7           16.18            20.18 
          1             6           27.34            39.28 
          2             5            91.65            67.31 
         3            21          104.79            85.07 
 
 
 
 
 
When Dsg 1 titres were correlated with severity of disease there was a 
trend to increasing titres with increasing severity of disease for Dsg 1. (Fig. 26) 
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Table 13:  Skin severity scores and  mean desmoglein 1 titres 
Figure 26:  Skin severity scores and mean desmoglein 1 titres 
with 95% confidence intervals 
Correlation of oral severity scores with desmoglein 3 titres  
 
 
      Score    
 
No of patients Mean titre  (U/ml)  Standard 
deviation 
          0            12           13.01            28.20 
          1             5          173.59             58.89 
          2            12           161.03            81.91 
         3            10          169.40            92.98 
 
 
 
 
Patients with oral lesions had higher titres than those without oral 
lesions. However there was no trend to increasing titres with increasing 
severity of disease. (Fig. 27) 
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Table 14:  Oral severity scores and mean desmoglein 3 titres 
Figure 27:  Oral severity scores and mean desmoglein 3 titres with 95% 
confidence intervals 
Correlation of Desmoglein 1 and  3 titres with prior number of 
relapses. 
 
 
There was no correlation between Desmoglein 3 titres and number of  prior 
relapses ( Fig. 28) 
 
 
 
There was no correlation between Desmoglein 1 titres and number of  prior 
relapses. (Fig.29) 
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Figure 28:  Desmoglein 3  titres and prior number of relapses 
Figure 29:  Desmoglein 1 titres and prior number of relapses 
DISCUSSION 
 
 Pemphigus is a life threatening blistering skin disease in which 
patients’ autoantibodies are directed against desmosomal glycoproteins, Dsg 
1 and Dsg 3. Rapid and accurate diagnosis is of utmost importance to enable 
early initiation of therapy. DIF and IIF studies are subjective, require 
experienced examiners and are expensive. IIF may detect a variety of 
antibodies against proteins of the extracellular matrix. Although Western 
immunoblotting and immunoprecipitation can be used to identify the target 
antigen in cases of pemphigus, these are time consuming, qualitative 
techniques, and impractical for routine screening of large numbers of serum 
samples. Dsg 1 and Dsg 3 ELISAs have been shown to provide a sensitive 
and highly specific assay for the diagnosis of PV and PF.7 Desmoglein  
ELISAs do not require a skilled observer and is a simple test to perform. 
Moreover it is able to differentiate PV from PF.92 Also it selectively detects 
antibodies against extracellular and conformational epitopes of desmoglein 
which include the most pathogenic antibodies in patients with PV.78 The 
primary aim of the study was to validate ELISA estimation of Dsg1 and Dsg3 
antibodies in pemphigus as a diagnostic test in Indian patients as there is a 
paucity of studies from India. 
 Our study over a period of 16 months included 39 patients with 
pemphigus and 36 controls. The different clinical types of pemphigus were 
diagnosed based on clinical features, histopathology and DIF. There were 2 
patients with oral pemphigus, 24 patients with mucocutaneous PV and 2 
patients with cutaneous pemphigus. Seven patients had PF. One patient each 
had pemphigus vegetans, pemphigus herpetiformis, IgA pemphigus and 
paraneoplastic pemphigus. Among the controls, nine patients had bullous 
pemphigoid, one patient each had chronic bullous dermatosis of childhood 
and epidermolysis bullosa acquisita. There were 13 patients with bullous 
impetigo, 2 patients with SSSS and 7 patients had Stevens Johnson 
syndrome-Toxic epidermal necrolysis overlap or TEN. 
The mean age of pemphigus patients in our study was 43.21 years. 
This was close to the mean age of 36.9 and 39.5 years previously reported in 
Indian studies whereas a higher mean age of onset has been reported from 
the UK.14,15 The male to female ratio in our study was 1:1.43. A study has 
noted no sex predilection in Indian patients.15 
Among the clinical variants in our study there was a predominance of 
PV patients which is consistent with other studies showing pemphigus vulgaris 
to be the most frequent subtype in India while pemphigus foliaceous was 
uncommon.14  
          The sensitivity and specificity of Dsg 1 ELISA was determined to be 
100% and 97.2% respectively. Dsg 3 ELISA  had a sensitivity and specificity of 
82.14% and 100% respectively. This is similar to the sensitivity and specificity 
reported in studies from India and abroad. 5,7,78 Sharma et al8  in a study from 
India on 27 patients with PV reported a sensitivity and specificity of 96.3% and 
92.3% for Dsg 1 and 85.2% and 100%  for Dsg 3 respectively.  Ishii et al6  
have reported a sensitivity and specificity of  94% and 96% for Dsg 3 ELISA 
and 96% and 96% for Dsg 1 ELISA respectively.  Lenz et al78 have reported 
both sensitivity and specificity of 93%  for Dsg 3 in IIF positive  patients.  
Amagai et al7 determined the sensitivity and specificity of Dsg1 to be 97.9% 
and 98.9% respectively and Dsg 3 to be 97.5% and 97.8% respectively. 
Harman et al5 have also reported similar results. Our results validate ELISA 
estimation of Dsg 1 and 3 antibodies in pemphigus to be a sensitive and 
specific test. False positivity was detected only in one HIV infected patient with 
SJS-TEN overlap. The polyclonal stimulation of antibodies in HIV may have 
resulted in false positivity though further studies are needed to elucidate this. 
All the other controls were negative for Dsg 1 and Dsg 3. In our study ELISA 
values were false negative in 2 pemphigus patients. One of them had IgA 
pemphigus and therefore IgG ELISA detected by the kit was found to be 
negative. The other was a patient with oral pemphigus of 3 years duration, 
who at the time of study had desquamative gingivitis.  
 When the diagnostic criteria for PV and PF proposed by Amagai et 
al7   was applied to this study group, the serodiagnosis matched the diagnosis 
in all (100%)  PF patients and 23 of the 28 (82.14%)  PV   patients. This was 
similar to the 86.8 % for PV and PF obtained by Amagai et al.7 The ability to 
differentiate PV from PF is a potential   advantage of ELISA over DIF and IIF. 
As in the study by Amagai et al7   the criteria was applied only to active cases.      
We also generated cut-off values for Dsg 1 and Dsg 3 ELISAs for the 
local population  using the receiver-operating-characteristic (ROC) analysis, as 
the Dsg 1 and Dsg3 ELISA kits were manufactured elsewhere with appropriate 
cut off values for that population. The sensitivity and specificity were plotted 
when different scores were used for cut-off values and the one which gave the 
highest score for the sum of sensitivity (%) and specificity (%) was determined 
to be the cut off value to be used.  For this analysis as in other studies data 
obtained with PF sera and control were used for Dsg 1 ELISA and data 
obtained with PV sera and control were used for Dsg 3 ELISA. This data will 
be useful for future studies as it will increase the sensitivity of the test. The cut-
off values were not used in this study to avoid using it on the same population 
from which it was generated. 
 Patients with oral lesions had significantly higher Dsg 3 titres when 
compared to patients without oral lesions. There was no correlation between 
skin lesions and Dsg 3 titres. Similarly patients with skin lesions had higher 
Dsg 1 titres than those without skin lesions. There was no correlation between 
Dsg 1 titres and oral lesions. Sharma et al8 were  also able to demonstrate a 
direct correlation between anti-Dsg 3 titres and severity of oral disease, and 
also between anti –Dsg 1 titres and  severity of cutaneous disease. Though 
Kumar et al9 obtained a wide range of values, Dsg 3 levels were higher in 
patients with extensive oral mucosal involvement  than those with mild or no 
mucosal involvement while severity of skin involvement had a direct 
relationship with levels of Dsg 1 antibodies. Amagai et al39  and Ding et al40 
have shown a difference in the antibody profile among mucosal dominant PV, 
mucocutaneous PV and PF.  However Sharma et al8 and Jamora et al82 found 
that the antibody profile did not correlate with the different morphological types.  
Sharma et al8 suggest that other factors such as genetic and racial influences 
or the effect of some minor antigens yet to be characterized may be 
considered to explain the differences.  
 When severity of disease graded between 0 to 3 separately for oral 
lesions and skin lesions was compared with antibody titres there was a trend 
for increase in Dsg 1 titres with increasing severity of skin disease. However 
though patients with oral disease had titres significantly higher than those 
without the disease, there did not seem to be much difference in titres 
between varying severity of disease. Amagai et al,7 Ishii et al6  and  Kumar et 
al9 have found parallel fluctuation of titres with disease activity. Harman et al81 
 found a wide range of values within each severity scores. They speculate that 
since pemphigus sera target multiple epitopes on both Dsg 1 and 3 molecules, 
it is possible that cases with minimal disease but high antibody levels may 
have a high proportion of non pathogenic antibodies either by virtue of their 
subclass or perhaps because they bind to epitopes that do not result in 
disease triggering. An alternative explanation they propose is that treatment 
may have dampened pathogenic mechanisms triggered by antibody binding in 
these cases. In cases of low ELISA values but active disease they suggest it is 
possible that the serum contains pathogenic antibodies to non desmoglein 
molecules or to epitopes on the intracellular domain of Dsg 1 or 3 which would 
be undetectable to ELISA.81 
There was no significant difference in titres of patient with acute onset 
and chronic active disease suggesting that treatment had not modified 
antibody levels. However there was only a small group of 8 patients with acute 
onset disease as compared to 31 patients with chronic active disease. Also all 
patients including the chronic active group of patients had active disease at 
the time sera was taken and therefore presumably had high titres of disease 
despite treatment. 
There was no significant relationship between duration of disease and 
ELISA titres.  However it is to be noted that though there was a wide range in 
the duration of disease  (0.6 to 108 months)  all patients had active disease at 
the time of study. 
We also analysed whether patients who have had multiple relapses had 
titres higher than those without. There seemed to be no significant difference 
in titres suggesting that patients with higher titres did not have more relapses. 
Others factors like rapid tapering and discontinuation of medication which 
might have caused a relapse were not studied.  
 
 Dsg 3 was positive in 23 (82.14%) of the 28 patients with PV, while 
Dsg 1 was positive in 18 (64.28%) of the 28. Dsg 1 was positive and Dsg 3 
was negative in all patients with PF. 
   
           Two PV patients in our study had only cutaneous lesions. They had no 
past history of oral lesions. Histopathology showed suprabasal bullae and DIF 
showed fishnet fluorescence for IgG rimming keratinocytes. They were 
diagnosed to have cutaneous pemphigus. While both patients had positive 
Dsg 1 both had negative Dsg 3. A similar study by Sharma et al8 have reported 
six patients with cutaneous pemphigus.8 All of them had elevated Dsg1 and 
four had positive Dsg 3. Yoshida et al64 studied 4 patients with cutaneous 
pemphigus and they have noted that during the course of treatment anti-Dsg 3 
IgG decreased more quickly than anti-Dsg1. One of our patients one had 
received oral steroids prior to presentation and this may explain why Dsg 3 
was negative. 
 Our study also included one patient with paraneoplastic pemphigus. 
He had an associated Castleman’s tumor. He presented with intractable 
stomatitis, ocular and genital lesions. Histopathology showed a suprabasal 
bulla and  DIF showed fishnet fluorescence for IgG and linear deposition for 
IgG and C3 along the basement membrane. Both Dsg 1 and 3 were elevated. 
Pateints with PNP raise antibodies against multiple antigens including 
desmoplakin I and II, BPAg1, envoplakin, periplakin, HD1/plectin  as well as 
desmogleins.89,90 Studies have shown that the association between clinical 
phenotype and anti-desmoglein autoantibody profile in PNP is not as clear as 
that in classic pemphigus. 91 
One of our patients had pemphigus herpetiformis. She presented with 
intensely pruritic  herpetiform lesions over the trunk and extremites without 
oral involvement. Histopathology revealed an intraepidermal bulla  and DIF 
showed fishnet fluorescence for IgG rimming the keratinocytes. Dsg 1 and 3 
were positive. A study on a large series of patients with pemphigus 
herpetiformis showed that the main target  autoantigen is Dsg 1 and that Dsg 
3 is detected in a few cases. 85 
 
 
The patient with IgA pemphigus presented with flaccid annular vesicles 
over the face, abdomen, elbows and legs. Histopathology showed an 
intraepidermal bulla. DIF showing fishnet fluorescence for IgA established the 
diagnosis. As expected, IgG antibodies to  Dsg 1 and 3 were detected to be 
negative in this patient. This was consistent with previous reports of absence 
of antibodies to Dsg 1 and Dsg 3 using ELISA for IgG antibodies. Hashimoto 
et al54 have demonstrated IgA antibodies to desmogleins in patients  with IgA 
pemphigus using a new ELISA for detecting IgA antibodies.   
            Patients with bullous disorders present physicians with formidable 
challenges. Precise diagnosis is important for determining treatment plans and 
for prognostication. Sensitive and specific testing for the pathogenic 
autoantibodies found in PV and PF would be helpful in the clinical 
management and laboratory investigation. 
Dsg 1 and Dsg 3 ELISAs evaluated in this study were  highly specific 
and sensitive technique for diagnosing pemphigus. Moreover it is possible to 
differentiate PV from PF. This new diagnostic tool will be useful in dermatology 
clinics  to make a rapid and accurate diagnosis especially where facilities for 
histopathology, DIF or IIF are not available.  
 
 
ELISA scores may be useful to plan tapering schedules of 
corticosteroids and to predict flares or relapses by detecting increase in 
antibody titres before clinical evidence of disease flares are noticed. Further 
prospective studies are needed to confirm this. Studies monitoring titres in 
patients in remission will provide useful data regarding correlation of titres with 
disease activity. Further studies are needed to determine whether the 
distribution of lesions affects antibody titres, due to the differential distribution 
of desmoglein in the body. 
 
 
 
CONCLUSIONS 
 
1. There were a total of 75 patients in the study consisting of 39 patients 
and 36 controls. The pemphigus patients had a mean age of 43.21 
years and the male to female ratio was 1:1.43. Among the clinical 
variants of pemphigus there was a predominance of PV patients  as 
seen in other studies.   
2. ELISA estimation of Dsg 1 antibodies in pemphigus had a sensitivity 
and specificity of 100% and 97.2% respectively. Dsg 3 estimation had a 
sensitivity and specificity of 82.14% and 100% respectively.  This is 
similar to the sensitivity and specificity reported from other studies. 
3. The cut off values with the highest sum of sensitivity and specificity for 
Dsg 1 and Dsg 3 ELISAs in the population studied were 17.79 and 
28.91 respectively. 
4. Dsg 3 was positive in 23 (82.14%) of the 28 patients with PV, while Dsg 
1 was postitive in 18 (64.28%) of the 28. Dsg 1 was posititve and Dsg 3 
was negative in all patients with PF.  
5. Using ELISA  for Dsg 1 and Dsg 3 antibodies, it is possible to 
differentiate PV from  PF. 
6. There was a significant correlation between the presence of mucosal 
disease and positive Dsg 3 antibodies, and the presence of cutaneous 
disease and positive Dsg 1 antibodies.   
7. There was a trend for increase in  Dsg 1 titres with increasing skin 
severity scores but no such trend was seen between increasing oral 
severity scores and Dsg 3 antibody titres.  
8. There was no significant difference in Dsg titres between patients with 
acute onset and chronic active disease. 
9. There was no correlation between Dsg titres and duration of disease. 
10. There was no correlation between Dsg titres and number of relapses. 
 
 
 
  
 
 
LIMITATIONS OF THE STUDY 
 
1) Due to financial constraints serial dilutions were not done for patients 
with high titres of antibodies to avoid the plateau effect. 
2) Follow up titres were not available to correlate Dsg titres with severity of 
disease. 
3) The ELISA  kit used detected only IgG antibodies. 
4) Severity of genital and conjunctival lesions were not scored. 
5) There were no patients with remittent disease. 
6)  There were only 8 patients who had not received immunosuppressive 
therapy prior  to  Dsg estimation. 
7) There was only one patient in each of the rarer variants of pemphigus in 
our study. This was insufficient to reach any significant conclusion. 
SUMMARY 
 
Pemphigus is an uncommon but formidable blistering disease. The 
current diagnostic tests are time consuming, require experienced examiners 
and are expensive. Recently ELISA estimation of Dsg antibodies has been 
shown to be a highly sensitive and specific test.    
 
         A cross sectional study was conducted between March 2005 and July 
2006. The study looked at the validity of ELISA estimation of Dsg 1 and Dsg 3 
antibodies in pemphigus as a diagnostic test. The ability to differentiate PV 
from PF was also studied. The correlation of desmoglein titres with mucosal 
and cutaneous disease, with severity of disease and prevalence  of Dsg 1 and 
3 antibodies in the various clinical variants were also studied.  
 
There were a total of 39 patients and 36 controls. In all patients, the 
diagnosis was based on clinical examination, histopathology and DIF findings. 
The mean age of the pemphigus patients was 43.21 years and the male to 
female ratio was 1:1.43. The clinical profile of patients was similar to that 
previously reported. 
 
We were able to validate ELISA estimation of Dsg antibodies as a 
diagnostic test for pemphigus with a sensitivity and specificity of 100% and 
97.2% for Dsg 1 and  sensitivity and specificity of 82.14% and 100% for Dsg 3 
respectively.  Serodiagnosis matched the diagnosis in 100% of PF patients 
and 82.14% of PV patients. There was a significant correlation between  
positive Dsg 1 antibodies and presence of skin lesions and  positive Dsg 3 
antibodies and presence of mucosal lesions. There was a trend for increase in 
Dsg 1 titres with increase in severity of cutaneous disease but this was not 
seen between Dsg 3 and mucosal disease. Prior treatment with steroids did 
not seem to modify titres when lesions were active. However there was no 
correlation between Dsg titres and duration of disease or between Dsg titres 
and number of prior relapses. Dsg levels can be a useful adjunct in the 
diagnosis of the rarer variants of pemphigus. 
 
Our study validates ELISA estimation of Dsg antibodies as a sensitive 
and specific test for the diagnosis of pemphigus in Indian patients. It will be 
particularly useful as a rapid and economical test in dermatology clinics 
especially where histopathology and DIF are not available.  
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 ANNEXURE I 
 
 
          INFORMED CONSENT DOCUMENT 
 
It has been explained to me that the study involves my examination. 
The necessity of investigations as well as need for regular follow up has been 
explained to me.  I also understand that the information I divulge is confidential 
and shall be used for study purposes only.  Thereafter I give my informed 
consent for the same. 
 
 
 
 
Date:      Signature of the patient/guardian 
CMCH, Vellore. 
 
 
 
 
 
 
 
ANNEXURE II 
PROFORMA  FOR PATIENTS 
S.No:                                                                                      Date: 
Name:  
Hospital  No: 
Age:  
Sex: 
Address: 
Diagnosis:   
Category: 
Duration of disease:     
Presenting complaints: 
Type of lesion            Duration                             Site 
 
Blisters\Erosions on skin 
Oral lesions 
Others 
 
  
Past History                              Yes/No                              
   
Oral lesions             
Skin lesions 
Treatment taken 
     Maximum             Current       Duration                 
     dose                       dose                              
Steroids 
   Oral 
   Injection 
   Topical 
Other immunosuppressants 
    Azathioprine 
    Cyclophosphamide 
    Cyclosporin 
    Mycophenolate mofetil 
    Others 
 
Prior Relapses (Yes/No) 
No         Date          Skin           Oral          Dose of steroid at relapse   
  
 
 
 
 
NO    DATE      ORAL SCORE           SKIN SCORE      DsG1       DsG3     
 
 
 
Investigations 
     1. Tzanck       
     2. Histology 
     3 . DIF 
  
ANNEXURE III 
PROFORMA  FOR CONTROLS 
S.No                                                                                      Date: 
Name:  
Hospital  No 
Age:  
Sex 
Address: 
Diagnosis:   
 
Duration of disease      
 
Presenting complaints 
Type of lesion            Duration                             Site 
 
Blisters\Erosions on skin 
Oral lesions 
Others 
 
 
 
Treatment taken 
           Maximum         Current           Duration   
           dose                  dose                              
Steroids 
   Oral 
   Injection 
   Topical 
Other immunosuppressants 
    Azathioprine 
    Cyclophosphamide 
    Cyclosporin 
    Mycophenolate mofetil 
    Others 
 
Investigations 
       Gram stain  
        Histopathology 
        DIF 
        Dsg 1 
        Dsg 3 
 
 
 
GLOSSARY TO THE MASTER TABLE 
AGE-Age in years 
SEX: 1=Male, 2=female 
GROUP: 1=Patients, 2=Controls 
DIAGN -Diagnosis: 1=Pemphigus vulgaris, 2=Pemphigus vegetans, 3=Pemphigus 
foliaceous, 4=Paraneoplastic pemphigus, 5=Pemphigus herpetiformis, 6=Chronic 
bullous dermatosis of childhood, 7=IgA pemphigus, 8=Oral pemphigus, 9=Bullous 
pemphigoid, 
10=Impetigo, 11=Stevens Johnson syndrome- toxic epidermal necrolysis 
(TEN)overlap / TEN, 12=Staphylococcal scalded skin syndrome, 13=Epidermolysis 
bullosa acquisita. 
CATE-Category: 1=Acute onset, 2=Chronic active, 3 =Remittent. 
DUR_SK-Duration of lesions in months 
 
For the following: 0= No, 1=Yes: 
PRIOR_S - Prior skin lesions 
PRIOR_O - Prior oral lesions 
SKIN_LE - Skin lesions at present 
ORAL_LE - Oral lesions at present 
 
OTHERS - Others sites involved: 0=No, 1=Genital, 2=Genital and conjunctival, 
3=Conjunctival  
 
For the following: 0= No, 1=Yes: 
HEAD - Lesions on the head  
TRUNK - Lesions on the trunk 
UL - Lesions on the upper limbs  
LL - Lesions on the lower limbs 
CURENT - Current treatment 
STEROI-Steroids 
ORAL-Oral steroids 
O_DO-Dose of oral steroids:0=No, 1=High>60mg, 2=Moderate=10-60, 
3=Low<10mg 
INJ-Injectable steroids: 0=No, 1=Yes  
I_DO- Dose of injectable steroids in mg;0=No, 1=High dose, 2=Low dose 
TOP-Topical steroids: 0=No, 1=Yes 
AZA-Azathioprine: 0=No, 1=Yes 
A_DO-Dose of Azathioprine in mg: 0=No, 1=50 mg, 2=100 mg 
CYP-Cyclophosphamide: 0=No, 1=Yes 
CYP_DO-Cyclphospamide dose in mg; 0=No, 1=50 mg, 2=100mg 
CYS-Cyclosporine: 0=No, 1=Yes 
CYS_DO-Cyclosporine dose in mg:0=No 
MMF-Mycophenolate moefetil: 0=No, 1=Yes 
M_DO-Myocphenolate dose: 0=No,1=1gm 
OTH-Others: 0=No, 1=Dapsone, 2=Methotrexate 
0_DO-Dose of othes in mg: 0=No, 1=25mg, 2=50mg 
PAST_R-Past treatment: 0=No, 1=Yes 
STEROI_1- Past treatment with steroids: 0=No, 1=Yes 
ORAL_1- Past treatment with oral steroids: 0=No, 1=Yes 
O_DO_1- Maximum dose of past treatment wih oral steroids in mg: 0=No,1=High 
>60 mg,2=Moderate 10-60, 3=Low <10mg 
O_DU- Duration of past treatment withoral steroids in months 
INJ_1-Past treatment with injectable steroids: 0=No, 1=Yes 
I_DO_1- Maximum dose of past treatment wih injectable steroids dose in 
mg:0=No,1=High,2=Low 
I_DU-Duration of past treatment with injectable steroids in months  
TOP_1- Past treatment with topical steroids: 0=No, 1=Yes 
T-DU-Duration of  past treatment with topical steroids  in months 
AZA_1- Past treatment with Azathioprine: 0=No, 1=Yes 
A_DO_1- Maximum dose of past treatment wih Azathioprine in mg:0=No, 1=50 mg, 
2=100 mg, 3=150mg 
A_DU-Duration of past treatment with Azathioprine in months 
CYP_1- Past treatment with Cyclophosphamide: 0=No, 1=Yes 
CYP_DO_1- Maximum dose of past treatment wih cyclphospamide in mg: 
0=No,1=50mg, 2=700mg 
CYP_DU-Duration of past treatment with cyclophosphamide in months 
CYS_1- Past treatment with cyclosporine: 0=No, 1=Yes 
CYS_DO_1- Maximum dose of past treatment wih Cyclosporine in mg: 0=No 
CYS_DU-Duration of past treatment with cyclosporine in months 
MMF_1-Mycophenolate moefetil: 0=No, 1=Yes 
M_DO-1- Maximum dose of past treatment wih Myocphenolate in mg:1=1500 mg 
M_DU-Duration of past treatment with mycophenolate moefetil in months 
OTH_1-Past treatment with other drugs: 1=Dapsone, 2=IV IG, 3=MTX, 
4=Ayurvedic, 5=Pyridostigmine, 6=Antibiotics, 7=Uknown, 8=ART 
0_DO_1- Maximum dose of past treatment wih others in mg: 1=<50, 2=50, 3=>50. 
O_DU-Duration of past treatment with others in months 
PRIR_Re-Pior relapses: 0=No, 1=1, 2=2, 3=3, 4=>3 
NUM-Number of prior relapses 
R1-Date of first relapse (dd/mm/yy) 
SKIN_1-Skin lesions at first relapse: 0=No, 1=Yes  
ORAL_1-Oral lesions at first relapse: 0=No, 1=Yes 
DS-S1-Dose of steroid at first relapse in mg 
R2-Date of second relapse (dd/mm/yy) 
SKIN_2-Skin lesions at second relapse: 0=No, 1=Yes  
ORAL_2-Oral lesions at second relapse: 0=No, 1=Yes 
DS-S2-Dose of steroid at second relapse in mg 
R3-Date of third relapse (dd/mm/yy) 
SKIN_3-Skin lesions at third relapse: 0=No, 1=Yes  
ORAL_3-Oral lesions at third relapse: 0=No, 1=Yes 
DS-S3-Dose of steroid at third relapse in mg 
 
 
  
 
 
R4-Date of fourth relapse (dd/mm/yy) 
SKIN_4-Skin lesions at fourth relapse: 0=No, 1=Yes  
ORAL_4-Oral lesions at fourth relapse: 0=No, 1=Yes 
DS-S4-Dose of steroid at fourth relapse in mg 
V1-Date of visit 
OS1-Oral score 
SS1-Skin score 
V1DSG1-Dsg 1 titre 
V1DSG3-Dsg 3 titre 
BIOPSY –Biopsy consistent with: 1=Pemphigus vulgaris, 2=Pemphigus vegetans, 
3=Pemphigus foliaceous, 4=Paraneoplastic pemphigus, 5=Bullous pemphigoid, 
6=Chronic bullous dermatosis of childhood, 7=Stevens Johnson syndrome-Toxic 
epidermal necrolysis overlap/Toxic epidermal necrolysis, 8=Oral pemphigus, 
9=Subepidemal bullous disorder, 10=IgA pemphigus, 11=Pemphigus herpetiformis.   
DIF-Direct immuofluorescence findings: 1=Fishnet fluorescence for IgG rimming 
epidermal keratinocytes,  2=1+linear fluorescence for IgG along basement membrane, 
3=Fishnet fluorescence  for IgA rimming keratinocytes, 4=Linear fluorescence for IgG 
and c3 along basement membrane, 5=Linear fluorescence for IgA along the basement 
membrane, 6=Negative  
  
 
 
 
 
 
Dsg-Desmoglein      Dsc-Desmocollin      PG-Plakoglobin 
DP-Desmoplakin    PP-plakophilin  
 
Fig. 1: Structure of desmosomes: The desmosome complex includes 
desmogleins and desmocolllins as transmembrane components, and 
plakoglobin, plakophilin and desmoplakin as cytoplasmic components.(28)  
  
Fig. 2: Desmoglein compensation hypothesis.Triangles represent the 
distribution of Desmoglein (Dsg) 1 and Dsg 3 in skin and mucous membrane. 
Anti-Dsg 1 antibodies in pemphigus foliaceous cause acantholysis only in the 
superficial epidermis of skin. In the deep epidermis and in mucous membranes, 
Dsg 3 compensates for antibody induced loss of function of Dsg 1. In early 
pemphigus vulgaris antibodies are present only against Dsg 3, which cause 
blisters only in the deep mucous membrane where Dsg 3 is present without 
compensatory Dsg 1. However in mucocutaneous pemphigus antibodies 
against both Dsg 1 and Dsg 3 are present and blisters form both in mucous 
membrane and skin. The blister is deep probably because antibodies diffuse 
from the dermis and interfere first with the function of desmosomes at the base 
of the epidermis.(13) 
 
 
Table 1: Clinical Variants of Pemphigus(10)  
 
 
 
Pemphigus vulgaris 
Variant :Pemphigus vegetans 
Pemphigus foliaceous 
    Variant : Pemphigus herpetiformis 
    Variant : Pemphigus erythematosus 
Induced Pemphigus 
Intercellular IgA dermatosis 
Paraneoplastic pemphigus  
 
 
 
 
 
 
 
 
 
 
 
 Table 2: Target antigens in Pemphigus28 
 
 
  Table 3: Direct immunofluorescence testing in pemphigus(28) 
 
 
   Dermatosis 
Principal 
immunoreactant
 
Site 
 
Pattern 
  
Pemphigus,all 
variants except 
 
IgG 
 
ICS 
 
Lace-like 
 
IgA pemphigus 
 
 
IgA 
 
 
ICS 
 
Lace-like 
 
Paraneoplastic 
Pemphigus 
 
IgG 
 
ICS 
 
Lace-like 
   
C3, IgG 
 
 
BMZ 
 
Linear 
  
C3, IgG 
 
 
BMZ 
 
Granular 
 
 ICS – Squamous intercellular substance   
 BMZ- Basement membrane zone  
  
 
 
Table 4: Diagnostic criteria for PV and PF 
Amagai et al82 have proposed a diagnostic criteria for PV and PF as below: 
 
 Desmoglein 1 Desmoglein 3 
               PV                +/-                    + 
               PF                +                    - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Legends to photos 
 
 
Fig. 4  Flaccid bulla of pemphigus vulgaris. 
Fig. 5  Extensive erosions of pemphigus vulgaris. 
Fig. 7 Superficial erosions of pemphigus foliaceus. 
Fig. 8  Herpetiform grouping of lesions in pemphigus herpetiformis. 
Fig. 10 Suprabasal bulla in an oral biopsy specimen x 25. 
Fig. 11 Subcorneal blister of pemphigus foliaceus x 20 
Fig. 13 DIF showing fishnet fluorescence rimming basal keratinocytes 
Fig. 14 DIF showing fishnet fluorescence rimming the full thickness of 
the epidermis 
Fig. 16 Erosions in a patient with bullous pemphigoid 
Fig. 17 Bulla in toxic epidermal necrolysis 
Fig. 19 Desmoglein ELISA kit 
Fig. 20 Equipment used for desmoglein ELISA test 
Fig. 21 Positive and negative desmoglein 1 and desmoglein 3 
